| Domain | Established findings | Evidence gaps / caveats | Suggested ontology terms | Key citations |
|---|---|---|---|---|
| Identifiers / synonyms | White-Sutton syndrome (WHSUS) is a rare neurodevelopmental disorder caused by heterozygous pathogenic variants in **POGZ**; OMIM **616364**. Related MONDO label reported as **intellectual disability-microcephaly-strabismus-behavioral abnormalities syndrome**; Open Targets also maps disease as **white-sutton syndrome**. Synonyms in the literature include **POGZ-related intellectual disability syndrome** and **POGZ-related neurodevelopmental disorder**. Disease-level information here is derived from aggregated published cohorts and curated disease resources, not EHR-only data. | MONDO/EFO mapping is resource-dependent in the gathered evidence; no single ICD-10/ICD-11 code was identified in the retrieved sources. | MONDO: **MONDO_0014606**; MeSH/ICD not established from gathered evidence | (pqac-00000002, pqac-00000008, pqac-00000017) |
| Causal gene / inheritance | Causal gene: **POGZ** (pogo transposable element derived with ZNF domain; Ensembl **ENSG00000143442**). Inheritance is **autosomal dominant / monoallelic**, most often **de novo**. In the 22-person cohort, 18/21 informative variants were de novo, 1 maternally inherited, 2 unknown; in the 117-patient aggregate, ~90% were de novo and ~10% inherited. | Penetrance is not well quantified; inherited cases show variable expressivity. Modifier genes are not established from the gathered evidence. | Gene: **POGZ**; inheritance: **autosomal dominant inheritance (HP:0000006)** | (pqac-00000005, pqac-00000008, pqac-00000009, pqac-00000017) |
| Variant spectrum | Predominantly **loss-of-function** variants: nonsense, frameshift, splice-site, larger deletions; missense variants are less common. In the 117-patient analysis: nonsense 41%, frameshift 40%, missense 8.5%, splice-site 7%, larger deletions 2.5%, in-frame deletions 1%. Variants often cluster in exon 19 / domains including proline-rich region, CENP-B DNA-binding and DDE transposase-related regions. Truncating variants predicted to **escape nonsense-mediated decay (NMD)** were associated with more severe phenotypes; missense and NMD-subjected variants tended to be milder. | Population allele frequencies (e.g., gnomAD counts) were not retrieved here. Functional classification of each specific variant remains case-dependent. Somatic disease role not supported; this is a germline disorder. | Sequence ontology suggestions: **stop_gained**, **frameshift_variant**, **splice_donor_variant**, **splice_acceptor_variant**, **copy_number_loss** | (pqac-00000004, pqac-00000005, pqac-00000009, pqac-00000016, pqac-00000017) |
| Core phenotype frequencies | Across the 22-person cohort: **speech delay 100%**, learning difficulties 100%, **motor delay 86%**, **intellectual disability 87%**, **autism 37.5%**; ocular abnormalities, hearing loss, gait abnormalities, GI and GU anomalies were common. Sleep-disordered breathing symptoms suggestive of OSA occurred in **4/12 (33%)** tested. In the 117-patient aggregate, commonly reported features included facial dysmorphism 96%, speech delay 88%, global developmental delay 88%, ID 79%, behavioral abnormalities 75%, sleep disturbances 75%, ocular anomalies 63%, hypotonia 54%, sensorineural hearing impairment 54%, microcephaly 46%, seizures 60% (noting ascertainment/reporting variability). In the 12-person series, microcephaly was **8/12**, early feeding problems **7/11**, obesity **4/5** among those >10 years. | Frequencies vary substantially across cohorts because of incomplete reporting, ascertainment bias, and different denominators. Some features such as subtle genital anomalies and brachydactyly are likely underreported. | HPO suggestions: **Global developmental delay (HP:0001263)**, **Speech delay (HP:0000750)**, **Intellectual disability (HP:0001249)**, **Autism (HP:0000717)**, **Hypotonia (HP:0001252)**, **Microcephaly (HP:0000252)**, **Sensorineural hearing impairment (HP:0000407)**, **Abnormality of gait (HP:0001288)**, **Obesity/Overweight (HP:0001513/HP:0025385)**, **Obstructive sleep apnea (HP:0002870)** | (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000006, pqac-00000009, pqac-00000010, pqac-00000017) |
| Mechanism / pathophysiology | **Human genetics + model evidence** support POGZ as a **chromatin regulator** interacting with **HP1α**, involved in **chromosome segregation**, **mitotic progression**, and transcriptional repression/organization. Mouse nervous-system knockout data show **transcriptional upregulation**, especially in cerebellum, enrichment of dysregulated genes in **neurogenesis** and **synaptic processes**, reduced mitotic cells in embryonic cortex, smaller brain, and **Purkinje-cell electrophysiologic abnormalities** (reduced simple/complex spike firing, increased inhibitory input amplitude). A plausible causal chain is: POGZ haploinsufficiency or abnormal truncated protein effect -> heterochromatin/transcription dysregulation and altered neuronal developmental programs -> abnormal circuit development/function, especially cerebellar pathways -> developmental delay, ID, motor and behavioral phenotypes. | Direct human tissue mechanistic studies remain limited. No disease-specific transcriptomic/proteomic biomarker is established from the retrieved human studies. Epigenetic episignature evidence for WHSUS was not retrieved. | GO suggestions: **chromatin organization**, **negative regulation of transcription**, **mitotic chromosome segregation**, **neurogenesis**, **synaptic signaling**; CL suggestions: **Purkinje cell**, **cortical intermediate progenitor cell** | (pqac-00000007, pqac-00000015, pqac-00000014, pqac-00000016) |
| Diagnostic approach | Diagnosis in published cohorts was usually made by **trio whole-exome sequencing**, **whole-genome sequencing**, or **intellectual-disability / neurodevelopmental gene panels**; some patients also had chromosomal microarray without an alternative diagnosis. Because the clinical phenotype is relatively nonspecific and variable, **genomic testing is the main diagnostic route**. In Baylor clinical exome data, POGZ variants were implicated in about **0.14%** of cases referred for neurodevelopmental indications. | No universally accepted clinical diagnostic criteria independent of molecular confirmation were identified. No validated biochemical biomarker, imaging signature, or episignature was retrieved from the gathered evidence. | NCIT/testing suggestions: **Whole Exome Sequencing**, **Whole Genome Sequencing**, **Next-Generation Sequencing Gene Panel**, **Chromosomal Microarray Analysis** | (pqac-00000004, pqac-00000006, pqac-00000017) |
| Management | Current care is **supportive and multidisciplinary**: developmental/behavioral assessment, speech-language therapy, occupational/physical therapy, hearing and vision evaluation, feeding/GI support, obesity monitoring, sleep assessment (including for OSA), and seizure-directed neurology care when indicated. Published case series emphasize individualized therapies tailored to neurological, behavioral, and communication needs. | No disease-modifying drug, gene therapy, RNA therapy, or targeted therapy was identified in the gathered evidence. Treatment response rates are not established at syndrome level. | NCIT suggestions: **Speech Therapy**, **Occupational Therapy**, **Physical Therapy**, **Behavioral Intervention**, **Audiologic Assessment**, **Ophthalmologic Examination**, **Nutritional Support** | (pqac-00000001, pqac-00000002, pqac-00000010, pqac-00000013) |
| Epidemiology / prognosis | WHSUS is rare; exact population prevalence/incidence were not established in the retrieved sources. Literature available to the cohorts indicated >50 reported individuals by 2020, ~90 by 2022, and 117 patients in an aggregate genotype-phenotype analysis. Course is typically **pediatric-onset and chronic/lifelong**, with variable severity from mild learning/behavioral issues to severe ID and multisystem involvement. Survival/life-expectancy data were not identified; no specific excess mortality estimate was retrieved. | Prevalence, incidence, penetrance, carrier frequency, and mortality remain insufficiently defined from the gathered evidence. Long-term adult natural history remains sparse. | HPO course suggestions: **Childhood onset**, **Chronic course**, **Variable expressivity** | (pqac-00000002, pqac-00000009, pqac-00000010, pqac-00000017) |
| Trials / current research | Identified study: **NCT07380594**, *Descriptive Study of Psychiatric Symptoms in White-Sutton Syndrome* (CHU Dijon; observational; recruiting; estimated n=30; first posted 2026-02-02). It aims to define psychiatric manifestations using interviews and standardized scales in genetically confirmed individuals aged >6 years. | No interventional White-Sutton syndrome trials were identified in the gathered evidence. The located study is observational and future-dated relative to the requested 2023-2024 emphasis. | NCIT suggestions: **Observational Study**, **Psychiatric Assessment**, **Questionnaire** | (pqac-00000013) |
| Models / comparative evidence | Best-supported model in gathered evidence: **nervous-system-specific conditional Pogz knockout mouse**. Reported phenotypes include microcephaly/smaller brain, growth impairment, altered embryonic neurogenesis, transcriptional dysregulation, cerebellar Purkinje-cell dysfunction, and behavioral abnormalities including learning and motor deficits, paralleling several human features. Earlier summaries also note **Drosophila** and possible **zebrafish** relevance, but detailed retrieved evidence here is strongest for mouse. | No naturally occurring veterinary disease equivalent was identified. Non-mouse models were mentioned in secondary discussion but not substantiated with detailed primary evidence in the gathered set. | Model ontology suggestions: **Mus musculus**; CL: **Purkinje cell**; UBERON: **cerebellum**, **cerebral cortex** | (pqac-00000001, pqac-00000012, pqac-00000014, pqac-00000015) |


*Table: This table provides a compact knowledge-base summary of White-Sutton syndrome using only evidence gathered in this conversation. It highlights established findings, major evidence gaps, suggested ontology mappings, and supporting citations for rapid curation.*